[go: up one dir, main page]

BRPI0518079A - usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica - Google Patents

usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica

Info

Publication number
BRPI0518079A
BRPI0518079A BRPI0518079-1A BRPI0518079A BRPI0518079A BR PI0518079 A BRPI0518079 A BR PI0518079A BR PI0518079 A BRPI0518079 A BR PI0518079A BR PI0518079 A BRPI0518079 A BR PI0518079A
Authority
BR
Brazil
Prior art keywords
rapamycin
hydroxymethyl
mtor inhibitor
hydroxy
ester
Prior art date
Application number
BRPI0518079-1A
Other languages
English (en)
Inventor
Jr Robert R Rufolo
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0518079A publication Critical patent/BRPI0518079A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Air-Conditioning For Vehicles (AREA)

Abstract

USOS DE UM INIBIDOR DE MTOR, DE UMA RAPAMICINA, E DE 42-éSTER DE RAPAMICINA COM áCIDO 3-HIDRóXI-2-(HIDROXIMETIL)-2-METILPROPIÈMCO, COMPOSIçãO FARMACêUTICA, E, EMBALAGEM FARMACêUTICA. A invenção provê o uso de um inibidor de mTOR no tratamento ou inibição de fibróides.
BRPI0518079-1A 2004-10-28 2005-10-21 usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica BRPI0518079A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62291704P 2004-10-28 2004-10-28
PCT/US2005/039836 WO2006050461A1 (en) 2004-10-28 2005-10-21 Use of an mtor inhibitor in treatment of uterine leiomyoma

Publications (1)

Publication Number Publication Date
BRPI0518079A true BRPI0518079A (pt) 2008-11-04

Family

ID=35768583

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518079-1A BRPI0518079A (pt) 2004-10-28 2005-10-21 usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica

Country Status (17)

Country Link
US (1) US7528145B2 (pt)
EP (1) EP1804779A1 (pt)
JP (1) JP2008518966A (pt)
KR (1) KR20070070184A (pt)
CN (1) CN101048152A (pt)
AU (1) AU2005302004A1 (pt)
BR (1) BRPI0518079A (pt)
CA (1) CA2585840A1 (pt)
CR (1) CR9068A (pt)
EC (1) ECSP077426A (pt)
IL (1) IL182748A0 (pt)
MX (1) MX2007005153A (pt)
NI (1) NI200700111A (pt)
NO (1) NO20071926L (pt)
RU (1) RU2007112787A (pt)
WO (1) WO2006050461A1 (pt)
ZA (1) ZA200703446B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220297A1 (en) 2002-02-01 2003-11-27 Berstein David L. Phosphorus-containing compounds and uses thereof
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
US8492110B2 (en) * 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
CA2850852A1 (en) * 2011-10-07 2013-04-11 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) * 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
CA2235036A1 (en) 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2000012799A (ja) * 1998-06-25 2000-01-14 Nec Ic Microcomput Syst Ltd 半導体メモリ装置とその製造方法
CN1293081C (zh) 1999-08-24 2007-01-03 阿里亚德基因治疗公司 28－表雷帕霉素类似物,其制备方法，药物组合物和用途
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
WO2002013802A2 (en) * 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20030144204A1 (en) * 2001-12-19 2003-07-31 Baylor College Of Medicine Akt-based inducible survival switch
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
CA2495085A1 (en) * 2002-08-12 2004-02-19 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
CA2496332A1 (en) * 2002-09-17 2004-04-01 Wyeth Oral formulations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법

Also Published As

Publication number Publication date
EP1804779A1 (en) 2007-07-11
AU2005302004A1 (en) 2006-05-11
KR20070070184A (ko) 2007-07-03
CR9068A (es) 2007-10-01
US20060094745A1 (en) 2006-05-04
US7528145B2 (en) 2009-05-05
WO2006050461A1 (en) 2006-05-11
CA2585840A1 (en) 2006-05-11
CN101048152A (zh) 2007-10-03
NI200700111A (es) 2008-01-17
RU2007112787A (ru) 2008-12-10
JP2008518966A (ja) 2008-06-05
NO20071926L (no) 2007-05-24
ECSP077426A (es) 2007-05-30
MX2007005153A (es) 2007-06-26
ZA200703446B (en) 2010-10-27
IL182748A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
CY1117272T1 (el) ΕΝΩΣΕΙΣ 3,4-ΔΙΫΔΡΟΠΥΡΑΖΙΝΟ[2,3-b]ΠΥΡΑΖΙΝ-2(1Η)-ΟΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΚΙΝΑΣΗΣ MTOR ΓΙΑ ΕΝΔΕΙΞΕΙΣ ΚΑΙ ΠΑΘΗΣΕΙΣ ΟΓΚΟΛΟΓΙΑΣ ΠΟΥ ΣΥΣΧΕΤΙΖΟΝΤΑΙ ΜΕ ΤΗΝ ΑΤΡΑΠΟ MTOR/P13K/AKT
BR0314397A (pt) Formulações orais
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EP2666472A3 (en) Uses and compositions for treatment of psoriatic arthritis
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0408024A (pt) combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BRPI0722051A2 (pt) Indicador de esterilização; uso de um indicador; e método de indicação da presença de átomos de oxigênio o e/ou nitrogênio n em um plasma presente em uma câmara pós-descarga.
CL2007002887A1 (es) Compuestos derivados de heterociclos, inhibidores de metaloproteinasa de la matriz (mmp); compuesto intermediario; composicion farmaceutica; kit farmaceutico; y uso en la prevencion y tratamiento en afecciones mediadas por metaloproteinasas de la mat
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2007003693A1 (es) Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
GT200500310A (es) Compuestos organicos
NO20062271L (no) CCI-779 for behandling av mantle celle lymfom
WO2007056184A3 (en) Azaindole compounds and use thereof as phospholipase-a2 inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.